North America Cell Line Development Market to reach USD 2.7 bn By 2024

 Request a sample

According to the Graphical Research new growth forecast report titled “North America Cell Line Development Market analysis based on Product, Source, Cell Line, Application, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2018 - 2024”, estimated to exceed USD 2.7 billion by 2024.

Growing demand for monoclonal antibodies, technological advancements in cell line development equipment and growing number of cancer incidences will drive North America cell line development market. Rising vaccine production, growth of biotechnology industry and high healthcare expenditure will drive business growth.

Presence of dominant industry players in U.S. focusing on developing advanced cell line development products coupled with favorable regulatory structure and innovation in development of biologics due to patent expiration will drive North America cell line development market. However, concerns pertaining to stem cell research will hinder industry growth over the forecast timeframe.  

Reagent and media product segment accounted for largest market share in 2017 and is estimated to follow similar trend over the coming years due to its numerous applications in development of regenerative medicines, bio production, drug discovery, tissue engineering toxicity testing and research. Non-mammalian source segment will witness considerable growth during the forecast period owing to its noteworthy applications in insecticide screening and toxicology study.

Hybridomas cell line type segment is forecasted to witness robust growth during the forecast timeframe. Hybridoma technology is most widely used process for large scale production of monoclonal antibodies.  The success of monoclonal antibodies in improving quality of life in patients suffering from cancer, autoimmune diseases and anti-inflammatory disorders have led to increased R&D for developing monoclonal antibodies for various critical health conditions will positively impact growth of cell line development market.

Canada cell line development market will grow considerably during the forecast period owing to numerous efforts undertaken by Canadian government to advance stem cell research and development of stable cell lines for bioproduction in the country. Growing awareness about cell-based therapy, innovation in development of biologics and rising prevalence of cancer will stimulate growth of Canada cell line development market.

Key industry players operating in North America cell line development market are Selexis, Sartorius, Lonza Group, Samsung Biologics, WuXi AppTec, GE Healthcare, Thermo Fisher Scientific, The European Collection of Cell Cultures, Sigma-Aldrich (Merck), GVK BIO, and Progenitor Cell Therapy. Industry players are adopting strategies including merger, acquisition and strategic collaboration and partnership to expand their product portfolio as well as augment consumer base in the industry.

Segments We Cover:

North America Cell Line Development Market By Product

  • Reagents and media
  • Equipment
    • Incubators
    • Centrifuges
    • Bioreactors
    • Storage equipment
    • Microscopes
  • Accessories

North America Cell Line Development Market By Source

  • Mammalian
  • Non-mammalian
    • Insects
    • Amphibians

North America Cell Line Development Market By Cell Line Type

  • Recombinant cell lines
  • Hybridomas
  • Continuous cell lines
  • Primary cell lines

North America Cell Line Development Market By Application

  • Bioproduction
  • Drug discovery
  • Toxicity testing
  • Tissue engineering
  • Research

The above information is provided for the following region and countries:

  • North America
    • U.S.
    • Canada